Mounjaro Drug Class: What Type of Drug Is Tirzepatide?

What drug class is Mounjaro in? People search this when a pharmacist, insurer or form asks for it, or when they want to know if Mounjaro is "like insulin" or "like Ozempic." Here is the short answer. Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist. That is the exact wording on its FDA label. It is the first drug in the US to act on both of these gut hormone receptors, which is why people call it a dual agonist. It is not insulin, not a sulfonylurea, and not a controlled substance.

What type of drug is Mounjaro?

Mounjaro is an incretin medicine. Incretins are hormones your gut releases after you eat. Two of them matter here: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both tell your pancreas to release insulin when blood sugar rises.

The label says tirzepatide "selectively binds to and activates both the GIP and GLP-1 receptors." In plain words, it copies two hormones at once. That helps:

• Lower blood sugar after meals, mostly when sugar is high (that is what "glucose-dependent" means).
• Slow how fast food leaves your stomach.
• Lower appetite, so people tend to eat less.

Tirzepatide is a peptide, a small protein chain built on the GIP hormone sequence with a fatty acid tail. The tail helps it stay in the body. The label lists a half-life of about 5 days, which is why it is a once-weekly shot under the skin.

If you want the basics of the GLP-1 side of this, our guide on how GLP-1 drugs work walks through it.

Mounjaro drug classification at a glance

Is Mounjaro insulin? No, and here is the difference

This is one of the most common searches, so it is worth being clear. Insulin is a hormone you inject to replace or add to what your pancreas makes. It lowers blood sugar no matter how high or low it is, which is why insulin can cause serious lows.

Mounjaro works upstream. It nudges your own pancreas to release insulin, and that effect is strongest when blood sugar is high. On its own, it has a lower risk of low blood sugar. The label warns that the risk goes up when Mounjaro is taken with insulin or with a sulfonylurea (like glipizide or glimepiride). Your prescriber may lower those other doses. Do not change them on your own.

Mounjaro vs Ozempic drug class

People often lump these drugs together as "GLP-1s." That is close, but not exact.

So Mounjaro sits in its own slot next to the GLP-1 receptor agonists. In the SURPASS-2 trial in type 2 diabetes, tirzepatide lowered A1C and weight more than semaglutide 1 mg. That does not mean it is the right pick for everyone. Our GLP-1 medication comparison lines up the main options.

Mounjaro indications: what it is FDA approved for

The Mounjaro label (revised August 2026) lists two uses:

1. Along with diet and exercise, to improve blood sugar in adults and children 10 years and older with type 2 diabetes.
2. To lower the risk of cardiovascular death, heart attack and stroke in adults with type 2 diabetes who are at high risk for these events. This was added on August 28, 2026, based on the SURPASS-CVOT trial. Our Mounjaro heart benefits guide explains that trial.

What is not on the Mounjaro label in the US:

• Weight loss without type 2 diabetes. That use is approved under the brand Zepbound.
• Obstructive sleep apnea. Also a Zepbound indication in the US, not a Mounjaro one. Some other countries, like Australia, have added sleep apnea to the Mounjaro label.
• Type 1 diabetes. Mounjaro is only approved for type 2.

Doctors sometimes prescribe a drug off-label, but insurers often cover only the labeled uses. Our Zepbound vs Mounjaro guide explains why the same drug carries two names.

Mounjaro drug class and ICD-10 codes

Many people type "mounjaro drug class icd 10" when filling out a prior authorization. Two quick facts:

• ICD-10 codes describe diagnoses, not drugs. There is no ICD-10 code for Mounjaro itself.
• For type 2 diabetes, codes start with E11 (type 2 diabetes mellitus), with more digits for details. ICD-10-CM also has Z79.85, "long-term (current) use of injectable non-insulin antidiabetic drugs," which can record that a person takes a drug like Mounjaro.

The right code depends on your chart. Your doctor's office chooses it, not you.

Why the drug class matters for your muscle

Because Mounjaro acts on two appetite pathways, many people eat much less. Eating less makes it easy to miss protein, and when weight drops fast, some of it can be muscle. Two habits help you keep it: hitting a daily protein target and doing regular strength work.

Sharpy is built for that. It sets one protein target, gives you one 20-minute workout a day, and its Shape Score shows whether you are losing fat, not muscle. For the dose steps the label lists, see our Mounjaro dosage chart; your prescriber decides your dose.

Common side effects tied to this drug class

The most common side effects on the label are stomach-related: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach pain. They are most common while the dose is going up. The label also warns about pancreatitis, gallbladder problems, low blood sugar with insulin or sulfonylureas, kidney problems from dehydration, and serious allergic reactions. Mounjaro can make some birth control pills less effective; our Mounjaro and birth control guide explains the label advice.

If you are pregnant, planning a pregnancy, under 18 or have had an eating disorder, talk to your doctor before starting or changing anything.

The bottom line

Mounjaro's drug class is GIP receptor and GLP-1 receptor agonist. It is a once-weekly incretin shot, not insulin, and not a controlled substance. In the US, it is approved for type 2 diabetes and for heart-risk reduction in high-risk adults with type 2 diabetes; weight loss and sleep apnea fall under Zepbound. Whatever brand you use, protecting muscle is your job, and Sharpy keeps your protein and workouts in one place. For the full story of the drug, start with our Mounjaro guide.

Sources

• DailyMed: Mounjaro (tirzepatide) prescribing information, updated August 27, 2026
• Eli Lilly: Mounjaro prescribing information
• Pharmacy Times: FDA approves tirzepatide to cut CV risk in type 2 diabetes (Aug 28, 2026)
• Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021
• CDC: ICD-10-CM browser tool